Massive Bio and Prognos Health Forge Strategic Partnership to Revolutionize Oncology Trial Access with AI-Driven Real-World Data Integration

Massive Bio, a leader in AI-powered oncology trial matching and patient access, has announced a strategic partnership with Prognos Health, a provider of actionable real-world data, to enhance access to cancer clinical trials and improve outcomes for patients. The collaboration combines Massive Bio’s clinical expertise and patient prescreening network with Prognos Health’s advanced data harmonization and enrichment capabilities to deliver powerful, real-time insights for pharmaceutical, biotech, and CRO clients. The integrated platform, set to launch in Q4 2025, will offer a comprehensive suite of solutions designed to streamline the clinical trial process. It leverages AI and event-driven data intelligence to identify eligible patients faster and more accurately, ensuring that no potential trial opportunity is missed. Massive Bio’s prescreening network currently supports around 50,000 cancer patients annually, with a goal to scale to 250,000 patients by 2027. Prognos Health brings access to fully integrated and harmonized lab and health records from more than 325 million de-identified patients, creating a rich, actionable dataset for oncology research. Bill Paquin, Chief Commercial Officer at Prognos Health, said, “Our expertise lies in transforming vast, fragmented lab data into meaningful, event-driven intelligence. Through this partnership, we’re not just delivering data—we’re tokenizing it to create dynamic, actionable signals that drive smarter decisions.” Selin Kurnaz, Ph.D., Co-founder and CEO of Massive Bio, added, “This is the nervous system for clinical trial enrollment. By combining our SYNERGY-AI platform with Prognos’ data layer, we achieve unprecedented speed and precision in identifying and matching patients. This integration enables real-time, intelligent interventions that empower clinicians and accelerate patient access to life-saving therapies.” Arturo Loaiza-Bonilla, M.D., M.S.Ed., Co-founder and Chief Medical Officer at Massive Bio, emphasized the practical impact on clinicians: “For oncologists, the volume of clinical data can be overwhelming. Our system cuts through the noise, providing a mission-control function that operates 24/7. It’s actionable intelligence at the point of care—empowering physicians, improving trial activation, and making the entire process scalable, data-driven, and truly patient-centric.” The partnership aligns with both companies’ missions: Massive Bio to expand access to advanced cancer treatments and Prognos Health to unlock the full potential of real-world data to improve health outcomes. As a founding member of the CancerX public-private initiative and a participant in the Cancer Moonshot White House program, Massive Bio continues to drive innovation across 17 countries with a global team of over 100 employees. Prognos Health remains a trusted partner in the life sciences industry, helping organizations accelerate therapy development and improve patient care through deep, integrated data insights.